Contraindications BPC-157 peptide therapy is not recommended for individuals who: Have active or recent cancer Are pregnant or breastfeeding Are under the age of 18 A full medical consultation is required before starting any peptide protocol
Medication is offered as a subscription service which you can cancel at any time
The Wolverine Stack Composition & Key Research Facts Components: BPC-157 (pentadecapeptide, 15 amino acids) and TB-500 (Thymosin Beta-4 fragment) Research designation: Widely referred to as the Wolverine Stack in the pre-clinical peptide research community BPC-157 primary mechanism: VEGFR2/ERK1/2 activation, nitric oxide signalling, fibroblast migration, angiogenesis, ECM stabilisation TB-500 primary mechanism: G-actin sequestration, cytoskeletal reorganisation, keratinocyte and endothelial cell migration, stem/progenitor cell mobilisation Synergy mechanism: BPC-157 organises and vascularises tissue
Some protocols recommend twice daily dosing even for injectable administration
In research discussions, GHK-Cu and BPC-157 are often viewed as complementary because they are commonly chosen for different tissue priorities
See the details in our CoQ10 & Ubiquinol Supplements Review , plus our Top Picks for CoQ10 and ubiquinol